Forty-one recent cases of invasive zygomycosis from a global clinical registry

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 2, 2009, Pages 296-302

  Ruping M J G T ^a   Heinz, W J ^b   Kindo, A J ^c   Rickerts, V ^d   Lass Florl C ^e   Beisel C , ^a   Herbrecth, R ^f   Roth, Y ^g   Silling, G ^h   Ullmann, A J ⁱ   Borchert, K ^j   Egerer, G ^k   Maertens, J ^l   Maschmeyer, G ^m   Simon, A ⁿ   Wattad, M ^g   Fischer, G ^o   Vehreschild, J J ^a   Cornely, O A ^a,p  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c SRI RAMACHANDRA UNIVERSITY   (India)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f HÔPITAL DE HAUTEPIERRE   (France)

^g TEL AVIV UNIVERSITY   (Israel)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁱ JOHANNES GUTENBERG UNIVERSITY   (Germany)

^j UNIVERSITY OF ROSTOCK   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m Ernst von Bergmann Clinic   (Germany)

ⁿ UNIVERSITY OF BONN   (Germany)

^o RWTH AACHEN UNIVERSITY   (Germany)

^p UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

Antifungal treatment; Breakthrough infections; Fungiscope ; Invasive fungal diseases

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASIA; BRAIN INFECTION; CHILD; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE REGISTRY; EUROPE; FEMALE; FUNGUS CULTURE; FUNGUS IDENTIFICATION; GEOGRAPHIC DISTRIBUTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION PREVENTION; LUNG MYCOSIS; MALE; MALIGNANT NEOPLASTIC DISEASE; MUCORMYCOSIS; MYCOCLADUS CORYMBIFER; NONHUMAN; ORBIT INFECTION; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PRESCHOOL CHILD; SCHOOL CHILD; SOFT TISSUE INFECTION; SURVIVAL RATE; SYSTEMIC MYCOSIS; TREATMENT RESPONSE; WEB BROWSER; ZYGOMYCETES;

EID: 77950255105     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp430     Document Type: Article

References (33)

1. Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48: 265-73.
2. Joshi N, Caputo GM, Weitekamp MR et al. Infections in patients with diabetes mellitus. N Engl J Med 1999; 341: 1906-12.
3. Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006; 25: 215-29.
4. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am 2002; 16: 895-914, vi.
5. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-60.
6. Spellberg B, Walsh TJ, Kontoyiannis DP et al. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48: 1743-51.
7. Pagano L, Offidani M, Fianchi L et al. Mucormycosis in hematologic patients. Haematologica 2004; 89: 207-14.
8. Pagano L, Valentini CG, Posteraro B et al. Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). J Chemother 2009; 21: 322-9.
9. Larkin JA, Montero JA. Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med 2003; 20: 201-6.
10. van Burik JA, Hare RS, Solomon HF et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61-5.
11. Greenberg RN, Mullane K, van Burik JA et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50: 126-33.
12. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-53.
13. Segal BH, Herbrecht R, Stevens DA et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-83.
14. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
15. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
16. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47: 503-9.
17. Almyroudis NG, Sutton DA, Fothergill AW et al. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007; 51: 2587-90.
18. Sun QN, Fothergill AW, McCarthy DI et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581-2.
19. Arikan S, Sancak B, Alp S et al. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol 2008; 46: 567-73.
20. Lekakis LJ, Lawson A, Prante J et al. Fatal Rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature. Biol Blood Marrow Transplant 2009; 15: 991-5
21. Schlemmer F, Lagrange-Xelot M, Lacroix C et al. Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 42: 551-2.
22. Kishel JJ, Sivik J. Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up. J Oncol Pharm Pract 2008; 14: 189-93.
23. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
24. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.
25. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-9.
26. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
27. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
28. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
29. Lass-Florl C, Resch G, Nachbaur D et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007; 45: e101-4.
30. Carrafiello G, Lagana D, Nosari AM et al. Utility of computed tomography (CT) and of fine needle aspiration biopsy (FNAB) in early diagnosis of fungal pulmonary infections. Study of infections from filamentous fungi in haematologically immunodeficient patients. Radiol Med 2006; 111: 33-41.
31. Ibrahim AS, Gebremariam T, Schwartz JA et al. Posaconazole monoor combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother 2009; 53: 772-5.
32. FDA. Drugs@FDA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022003s007lbl.pdf (1 November 2009, date last accessed).
33. Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001; 32: 851-4.